Topic outline

  • M-protein diagnostics of Multiple Myeloma patients treated with biologics

    Hans JacobsSpeaker: J.F.M. (Hans) Jacobs (NL)

    Moderator: Christopher McCudden (CA)

    Recorded on  27th March 2018 at 14:00 CET


    Treatment of multiple myeloma (MM) has substantially changed with the recent introduction of therapeutic monoclonal antibodies (mAb) which have further improved the rates and depth of clinical response. mAb therapy in MM patients has introduced new challenges in how therapy responses can be defined. On the one hand, recently approved mAb interfere with routine M-protein diagnostics. On the other hand, given the high rates of complete responses, new response categories need to be defined to measure minimal residual disease. As a reaction to these challenges research has focused on adaptations of conventional M-protein diagnostics to mitigate interference and on the introduction of novel methods that enable the identification of minimal residual disease. The aim of this e-seminar is to discuss how mAb therapy has changed both the therapeutic as well as the diagnostic landscape of MM.

    About the speaker

    Dr. J.F.M. (Hans) Jacobs. M.D., Ph.D.
    Dr. Jacobs works as Laboratory Specialist Medical Immunology at the Radboud University Medical Centre, Nijmegen, The Netherlands. He is specialized in onco-immunology, monitoring cancer-immunotherapy trials, and biomarker development for IVD applications. As head of the national reference centre for M-protein diagnostics at the Radboudumc, dr. Jacobs coordinates the Dutch External Quality Assessment program for M-protein diagnostics since 2012. He is national board member the SKML section Humoral Immunology and National board member Kalibration-2000. Within the IFCC framework, dr. Jacobs is involved in the harmonization and standardization of M-protein diagnostics. Dr. Jacobs is co-author of more than 60 international articles and book-chapters. Since 2016 he is member of the editorial board of ‘Clinical Chemistry and Laboratory Medicine’. Dr. Jacobs teaches immunology courses at the Radboudumc and the University of Twente.

    Dr. Jacobs is awarded with:

    • 2017 KWF Young Investigator Grant (Dutch Cancer Society)
    • 2016 Young Investigator Award Dutch Society of Clinical Chemistry
    • 2016 Research Grant Radboudumc Oncology Foundation
    • 2013 Kalibration-2000 Grant
    • 2012 Noyons Grant
    • 2012 ZonMW Veni Grant (The Netherlands Organisation for Scientific Research)
    • Assessment & Certificate